Xeris Biopharma Holdings (XERS) Shares Outstanding (Weighted Average) (2020 - 2026)

Xeris Biopharma Holdings has reported Shares Outstanding (Weighted Average) for 7 years, with the latest figure at $170.5 million in Q1 2026.

• For the quarter ending Q1 2026, Shares Outstanding (Weighted Average) rose 11.86% year-over-year to $170.5 million; the trailing twelve-month figure through Mar 2026 stood at $170.5 million (up 11.86% YoY), and the FY2025 full-year result was $160.4 million, up 9.3% from the prior year.
• Shares Outstanding (Weighted Average) for Q1 2026 stood at $170.5 million, up from $160.4 million in the prior quarter.
• The five-year high for Shares Outstanding (Weighted Average) was $170.5 million in Q1 2026, with the low at $94012.0 in Q2 2022.
• Historically, Shares Outstanding (Weighted Average) has averaged $121.8 million across 5 years, with a median of $140.5 million in 2024.
• Annual changes were most pronounced in 2022 — Shares Outstanding (Weighted Average) plunged 99.85% — and 2024, when it surged 155159.11%.
• Xeris Biopharma Holdings' Shares Outstanding (Weighted Average) stood at $135.6 million in 2022, then gained by 1.51% to $137.7 million in 2023, then advanced by 6.61% to $146.8 million in 2024, then climbed by 9.3% to $160.4 million in 2025, then advanced by 6.29% to $170.5 million in 2026.
• The last three Shares Outstanding (Weighted Average) figures came in at $170.5 million (Q1 2026), $160.4 million (Q4 2025), and $163.6 million (Q3 2025), per Business Quant data.